Generic Drug Makers Seek Accurate, Complete Inactive Ingredients Database

Generic drug industry officials raised concerns about the completeness and accuracy of the Inactive Ingredients Database (IID), as well as FDA policies regarding inactive ingredients in generic drugs, at a recent agency meeting on generic drug user fee implementation. Industry also complained about the increase in fees for smaller businesses and the reduction in communication between the agency and manufacturers. The meeting last Wednesday (Sept. 17) was held to solicit public comments on certain user fee implementation issues and to...